284 related articles for article (PubMed ID: 23455076)
21. Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.
Zhao B; Zhao H
Oncotarget; 2017 Nov; 8(55):93813-93824. PubMed ID: 29212191
[TBL] [Abstract][Full Text] [Related]
22. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Je Y; Schutz FA; Choueiri TK
Lancet Oncol; 2009 Oct; 10(10):967-74. PubMed ID: 19767240
[TBL] [Abstract][Full Text] [Related]
23. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
Choong NW; Kozloff M; Taber D; Hu HS; Wade J; Ivy P; Karrison TG; Dekker A; Vokes EE; Cohen EE
Invest New Drugs; 2010 Oct; 28(5):677-83. PubMed ID: 19649772
[TBL] [Abstract][Full Text] [Related]
25. Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis.
Gao C; Wang J; Li Y; Zhao H; Li R; Hou L; Zhang Y; Tian S; Liang H; Wang C; Chen X; Wang J
Medicine (Baltimore); 2018 Aug; 97(34):e11860. PubMed ID: 30142779
[TBL] [Abstract][Full Text] [Related]
26. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.
Sui JD; Wang Y; Wan Y; Wu YZ
Drug Des Devel Ther; 2018; 12():1645-1657. PubMed ID: 29922039
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
Ewer MS; Suter TM; Lenihan DJ; Niculescu L; Breazna A; Demetri GD; Motzer RJ
Eur J Cancer; 2014 Aug; 50(12):2162-70. PubMed ID: 24930624
[TBL] [Abstract][Full Text] [Related]
29. Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer.
Gkountouvas A; Kostoglou-Athanassiou I; Veniou E; Repousis P; Ziras N; Kaldrimidis P
Thyroid; 2010 Jun; 20(6):597-600. PubMed ID: 20553195
[TBL] [Abstract][Full Text] [Related]
30. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
[TBL] [Abstract][Full Text] [Related]
31. Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.
Carlisle B; Demko N; Freeman G; Hakala A; MacKinnon N; Ramsay T; Hey S; London AJ; Kimmelman J
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26547927
[TBL] [Abstract][Full Text] [Related]
32. Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor.
Komatsu Y; Ohki E; Ueno N; Yoshida A; Toyoshima Y; Ueda E; Houzawa H; Togo K; Nishida T
Jpn J Clin Oncol; 2015 Nov; 45(11):1016-22. PubMed ID: 26373318
[TBL] [Abstract][Full Text] [Related]
33. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.
De Giorgi U; Rihawi K; Aieta M; Lo Re G; Sava T; Masini C; Baldazzi V; De Vincenzo F; Camerini A; Fornarini G; Burattini L; Rosti G; Moscetti L; Chiuri VE; Luzi Fedeli S; Ferrari V; Scarpi E; Amadori D; Basso U
J Geriatr Oncol; 2014 Apr; 5(2):156-63. PubMed ID: 24495699
[TBL] [Abstract][Full Text] [Related]
34. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis.
Petrelli F; Ardito R; Borgonovo K; Lonati V; Cabiddu M; Ghilardi M; Barni S
Eur J Cancer; 2018 Nov; 103():7-16. PubMed ID: 30196108
[TBL] [Abstract][Full Text] [Related]
35. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
[TBL] [Abstract][Full Text] [Related]
36. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
[TBL] [Abstract][Full Text] [Related]
37. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
38. Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials.
Wang C; Li J
J Clin Pharm Ther; 2021 Jun; 46(3):571-584. PubMed ID: 33421183
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
